Citations

Clear

4610 citation(s) found for "Lu, Brian".

Lung-targeted lipid nanoparticle delivery of a matricellular mRNA promotes fibrotic lung repair
Betageri, Kalpana R. , Meridew, Jeffrey A., Parrett, Brian J. , Gilbert, Rachel M. , Link, Patrick A. , Schussler, Nichole A, Mercado‐Perez, Arnaldo , Tschumperlin, Daniel J. , Link, Patrick A , Schussler, Nichole A, Caporarello, Nunzia , Barry, Michael A.

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | October 14, 2025 | Volume: 74 | Issue: 4 | Pages: 445-453

10.1165/rcmb.2025-0247oc | PMID 41086370 Get It

Abstract Pulmonary fibrosis is increasingly understood to involve dysfunction within and across multiple cellular compartments, with recent attention highlighting the involvement of pulmonary vascular dysfunction in failed repair and progression of fibrosis. Formulation and delivery of lung-targeting lipid nanoparticles (LNPs) may provide a means to selectively target the lung but not systemic vasculature. However, the feasibility and efficacy of such approaches in the fibrotic lung are unknown. We sought to test whether intravenously administered lung-targeting LNPs can safely deliver mRNA to the healthy and fibrotic lung vasculature in young and aged mice and whether delivery of mRNA encoding a matricellular protein could promote fibrosis resolution. We used a selective organ targeting LNP formulation and characterized cell-specificity of delivery after bleomycin-induced lung fibrosis. We then delivered Ccn3 mRNA (encoding cellular communication network factor 3) to aged mice in the setting of established lung fibrosis and evaluated fibrotic regression and vascular repair. The matricellular protein encoded by Ccn3 was previously identified by our group as an important regulator of lung endothelial function. We found that LNP delivery was lung specific and predominantly endothelial targeting in the setting of lung fibrosis. Delivery of Ccn3 mRNA to aged mice via LNPs modestly reduced fibrosis and improved microvascular density in the lungs. Our results support the concept that cell-specific and repair-promoting cargos delivered via lung-targeting LNPs may have utility for treatment of established fibrosis.
Stiff Person Syndrome in the Hospice Patient: A Case Report and Discussion
Svendsen, Molly, Layton, Brian, Etzioni, Shiri, Edwin, Mark, Layton, B Parker, Svendsen, Molly , Layton, B. Parker, Etzioni, Shiri

Mayo Clinic

Journal of Palliative Medicine | October 13, 2025 | Volume: 29 | Issue: 8 | Pages: 1175-1177

10.1177/10966218251387432 | PMID 41081611 Get It

Stiff Person Syndrome (SPS) is a rare, progressive autoimmune neurological disorder characterized by painful spasms, muscle rigidity, and heightened sensitivity to external stimuli. Management often relies on therapies that fall outside standard hospice formularies, creating challenges in end-of-life care for affected individuals. We present the case of a 57-year-old woman with metastatic colorectal cancer and SPS whose primary concern in transitioning to hospice was the risk of symptom destabilization if standard neurological treatments, including intravenous immunoglobulin and intrathecal baclofen, were discontinued. Through close interdisciplinary collaboration among palliative care, neurology, and the hospice team, an individualized plan of care was developed that preserved access to symptom-modifying treatments while aligning with the hospice philosophy. Environmental and pharmacologic strategies—including diazepam, levetiracetam, and anticipatory planning—were employed to address evolving symptoms, resulting in effective symptom control and avoidance of hospital readmission. This case highlights the need for flexible, patient-centered approaches in hospice care for rare neurological conditions like SPS. Continuation of disease-specific therapies for symptom palliation can be ethically and clinically appropriate when integrated with clear goals of care. Adaptable interdisciplinary models are essential to attend to quality of life and support care that is in alignment with patient values at the end of life.
Musculoskeletal trauma rehabilitation: a global comparison
Bernstein, Brian , Lundy, Douglas W. , Miclau, Theodore , Balogh, Zsolt J. , Kitada, Shimpei , Leighton, Ross , Putzeys, Guy , Padilla-Rojas, Luis G. , Vallejo, Linda, Tamayo-Cosio, Jonathan, Zertuche, Darío Esaú Garín , Herrera, Cristian A. Rojas, Hungria, José Octavio Soarez, Camacho, Jaime A. Leal, Caiero, Marcelo Tadeu , Neyra, Horacio Tabares, Pape, Hans‐Christoph , Miclau, Theodore A, Schipper, Inger Birgitta , Herrera, Cristian A. Rojas, Hungria, José Octávio Soares , Leal, Jaime Andrés , Giordano, Vincenzo

Mayo Clinic

OTA International | October 13, 2025 | Volume: 8 | Issue: 6S | Pages: No page available

10.1097/oi9.0000000000000437 | PMID 41098362 Get It

Abstract Rehabilitation after musculoskeletal trauma is globally acknowledged as essential for restoring function and improving quality of life; however, significant variation exists in rehabilitation frameworks and services worldwide. Although certain principles—such as early intervention, structured care pathways, and multidisciplinary approaches—are universally recognized as important determinants of outcomes in trauma patients, their implementation and effectiveness vary considerably due to differences in health care infrastructure, economic resources, policy frameworks, and cultural contexts. Drawing on comparative analyses of rehabilitation frameworks across regions, including North America, Latin America, Europe, Asia-Pacific, and Africa, this paper identifies structural variations, systemic challenges, and innovations that can inform global rehabilitation efforts. Strategic international collaboration focusing on shared learning, standardized protocols, technology integration, and targeted investments is key to creating equitable and sustainable rehabilitation models, especially in resource-limited settings and aging populations.
2-Chloroprocaine and Bupivacaine Are Unreliable Indicators of Intravascular Injection in the Premedicated Patient
Mulroy, Michael F., Neal, Joseph M., Mackey, David C., Harrington, Brian E.

Mayo Clinic

Regional Anesthesia & Pain Medicine | October 11, 2025 | Volume: 23 | Issue: 1 | Pages: 9-13

10.1136/rapm-00115550-199823010-00004 Get It

Background and Objectives Epinephrine-containing test doses for detection of intravascular injection during epidural anesthesia may be unreliable or hazardous in beta-blocked, elderly, or pregnant patients. Subtoxic injections of lidocaine have been used as an alternative marker of intravascular injection in unpremedicated patients. We studied two groups of premedicated patients and unpremedicated subjects to evaluate the reliability of the local anesthetics bupivacaine (B) and 2-chloroprocaine (2-CP) as test dose injections. Methods Thirty ASA I and II subjects received blinded randomized injections of 2-CP, B, or normal saline via a peripheral vein. Results In group I, 10 healthy unpremedicated volunteers universally recognized injection of 90 mg 2-CP or 25 mg B, but did not reliably detect the injection of 60 mg 2-CP. In group II, 20 patients premedicated with 1 μg/kg fentanyl and 30 μg/kg midazolam could not reliably detect similar injections. Sixteen responded to the injection of 90 mg 2-CP, while 13 detected the 25 mg B test dose. A blinded observer rated only 12 of the subjective reports as conclusive of detection of intravascular injection after each drug. There were no false-positive reports in any group. Conclusions While 90 mg 2-CP or 25 mg B may be reliable alternatives to epinephrine test doses in unpremedicated subjects, they are unreliable indicators of intravascular injection in the premedicated patient.
7-T MRSI Mapping of Glutamate and Glutamine in Diffuse Gliomas
Burkett, Brian J. , Port, John D. , Port, John D , Burkett, Brian

Mayo Clinic

Radiology: Imaging Cancer | October 10, 2025 | Volume: 7 | Issue: 6 | Pages: No page available

10.1148/rycan.250464 | PMID 41071074 Get It

Iso-osmotic contrast filling of an artificial urinary sphincter is a safe and effective tool for diagnosis of mechanical failure
Robinson, Maraika , Linder, Brian J. , Elliott, Daniel S. , Robinson, Maraika O , Linder, Brian J

Mayo Clinic

Investigative and Clinical Urology | October 10, 2025 | Volume: 66 | Issue: 6 | Pages: 534

10.4111/icu.20250150 | PMID 41184147 Get It

Nonsurgical Management of Syndrome of the Trephined: A Systematic Review
Paul, Brian K. , Leach, Garrison A., Holcombe, Travis C., Paul, Brian

Mayo Clinic

Journal of Craniofacial Surgery | October 9, 2025 | Volume: 37 | Issue: 1/2 | Pages: e81-e82

10.1097/scs.0000000000012042 | PMID 41066633 Get It

Syndrome of the Trephined (SoT), also known as sunken or sinking skin flap syndrome (SSFS), is a rare sequela of decompressive craniectomy caused by an atmospheric pressure gradient over the underlying brain parenchyma following bone flap removal. Cranioplasty is the definitive treatment of SoT, although some patients are not surgical candidates or require bridging to definitive treatment. This systematic review identified 7 articles describing nonsurgical interventions for patients with SoT. Three treatment modalities emerged: external orthotics, scalp traction, and Trendelenburg positioning. These approaches demonstrated rapid improvements in neurological symptoms, including restored motor function, improved cognition, resolution of midline shifts, and, in some cases, re-expanded brain parenchyma. While these results are limited to case reports and small case series, they demonstrate promising early outcomes for the noninvasive management of Syndrome of the Trephined.
Perioperative Change in Bone Quality Following Posterior Cervical Fusion and Its Effects on Postoperative Outcomes
Levy, Hannah A. , Messer, Caden, Vallecillo, Tissiana, Allen, Tyler, Townsley, Sarah, Bydon, Mohamad , Fogelson, Jeremy L. , Elder, Benjamin D. , Currier, Bradford L. , Freedman, Brett A. , Sebastian, Arjun S. , Nathani, Karim, Vallecillo, Tissiana , Pinter, Zachariah W. , Salmons, Harold I. , Nathani, Karim Rizwan , Nassr, Ahmad , Karamian, Brian A.

Mayo Clinic

Clinical Spine Surgery | October 9, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/bsd.0000000000001922 | PMID 41065382 Get It

Study Design: Retrospective cohort analysis. Objective: To determine the effect of long-segment posterior cervical decompression and fusion (PCDF) on perioperative changes in vertebral Hounsfield Units (HUs) and the impact of these changes on radiographic outcomes and fusion status. Summary of Background Data: Low preoperative CT HUs have been associated with adverse outcomes after spinal fusion, including hardware complications and reoperation. No existing studies have investigated the preoperative to postoperative change in HUs after cervical spinal fusion. Stress shielding may decrease bone quality within the fusion construct. Whereas, altered junctional loading and increased segmental mobility may precipitate bony hypertrophy in the terminal and adjacent levels. Methods: All adult patients who underwent C2-T2 PCDF for myelopathy/ myeloradiculopathy at an academic center between 2013 and 2020 were retrospectively identified. Preoperative and postoperative HUs were assessed on axial CT images in the cranial, middle, and caudal C2, C6, T2, and T3 vertebral bodies, outside of the region of instrumentation and artifact by 2 independent reviewers. Paired t test compared preoperative to postoperative changes in HUs. Preoperative and long-term postoperative cervical alignment, fusion, and revision rates were assessed. Univariate and regression analysis compared patient factors and outcomes between groups with perioperative increase versus decrease in vertebral HUs. Results: One hundred patients were included. The average preoperative to postoperative change in HUs in the C2, C6, T2, and T3 vertebral bodies were −19.80 (P=0.008), −52.63 (P<0.001), 15.15 (P=0.014), and 9.41 (P=0.346), respectively. Perioperative increase in C2 HUs was predictive of increased postoperative distal junctional angle (β=3.41, P=0.048) and increased T1–T4 kyphosis (β=6.50, P=0.003). Perioperative increase in C6 HU predicted pseudoarthrosis (fusion odds ratio: 0.19, P=0.007). Conclusions: Significant perioperative decreases in C6 HUs within a long-fused construct may demonstrate stress shielding. The significant association between greater distal kyphosis and an increase in C2 HUs may be attributed to a stress riser effect. Level of Evidence: Level III.
Abstract Wed136: Integration of Mechanistic Fontan Circulatory Models with Interpretable Machine Learning Classifiers
Schenk, Noah A. , Egbe, Alexander , Beard, Daniel , Carlson, Brian E.

Mayo Clinic

Circulation Research | October 8, 2025 | Volume: 137 | Issue: Suppl_1 | Pages: No page available

10.1161/res.137.suppl_1.wed136 Get It

Introduction/Background: Despite numerous medical advances, 30% of patients with Fontan circulation require heart transplantation by 21. Current risk stratification relies on clinical metrics that lack strong correlations to patient outcomes, leading to a high waitlist mortality. Hypothesis: Integration of physics-based hemodynamic modeling with interpretable machine learning will improve prediction of patient outcomes (listing for heart transplant and/or cardiac death) by quantifying physiologic mechanisms inaccessible through clinical measures alone. Goals/Aims: 1. Develop a lumped-parameter mechanistic model (LPMM) of Fontan circulation 2. Identify patient clusters and predictors of patient outcomes 3. Validate model-informed classifiers against clinical-only approaches Methods/Approach: A LPMM incorporating ventricular sarcomere mechanics, atrial hemodynamics, and vascular viscoelastic effects was optimized to cardiac catheterization and echocardiography data from 51 patients (age 25±8 years). Thirty-eight parameters (ventricular inotropy, atrial stiffness, pulmonary elastance, etc.) were calibrated via surrogate optimization, minimizing least-squares error versus 11 clinical targets. Partial least-squares regression with leave-one-out cross-validation compared clinical-only versus model-informed classifiers of outcomes. Results/Data: The LPMM achieved 2% mean error across hemodynamic targets, with CVP and pulmonary pressures matching clinical measurements within 1%. Model-derived minimum atrial pressure (4.46±1.78 vs 2.68±0.87 mmHg, p<0.05) outperformed all clinical variables in discriminating patient outcomes. Integration of LPMM parameters increased AUROC from 0.67 to 0.78 for patient outcome prediction. Conclusions: Physics-based modeling identifies ventricular passive stiffness, atrial end-diastolic volume, and minimum atrial pressure, along with patient age (a clinical value) as critical determinants of Fontan failure. Combined mechanistic-machine learning approaches enable phenotype-specific risk stratification, supporting earlier referral for advanced therapies. This methodology establishes a framework for precision management of complex congenital circulations.
Adaptation and Performance of the Self‐Report‐Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort
Cerhan, James R. , Соколова, Т. Н. , Cahn, Elliot, Tsang, Mazie , Strouse, Christopher , Hildebrandt, Michelle A.T. , Feldman, Andrew L. , Jaye, David L. , Martin, Peter , Cohen, Jonathon B. , Lossos, Izidore S. , Friedberg, Jonathan W. , Thompson, Carrie A. , Flowers, Christopher R. , Sokolova, Tereza, Cahn, Elliott J, Strouse, Christopher S , Rosenthal, Allison , Feldman, Andrew L , Jaye, David L , Martin, Peter , Cohen, Jonathon B , Kahl, Brad S , Lossos, Izidore S , Friedberg, Jonathan W , Nastoupil, Loretta J , Link, Brian K , Habermann, Thomas , Maurer, Matthew , Casulo, Carla , Thompson, Carrie A , Williams, Annalynn M , Flowers, Christopher R , Cerhan, James R , Hildebrandt, Michelle A T , Tsang, Mazie , Sokolova, Tereza, Kahl, Brad S. , Nastoupil, Loretta J. , Link, Brian K. , Habermann, Thomas M. , Maurer, Matthew J. , Casulo, Carla

Mayo Clinic

Hematological Oncology | October 8, 2025 | Volume: 43 | Issue: 6 | Pages: No page available

10.1002/hon.70137 | PMID 41057230 Get It

ABSTRACT Newly diagnosed patients with non‐Hodgkin lymphoma (NHL) often have a history of other diseases, and these comorbidities can impact patient treatment and management options, as well as overall survival (OS). We developed the Lymphoma Epidemiology of Outcomes (LEO) comorbidity index (LCI) as a sum of 10 comorbidities adapted from the Self‐Report‐Generated Charlson Comorbidity Index (SRG‐CCI) for use in the LEO cohort, a national prospective study of newly diagnosed NHL. Of the 5502 participants with self‐reported comorbidity data, 3107 (56.4%) were male and the mean age at diagnosis was 60.9 years (range, 18–99 years). The LCI ranged from 0 to 6, with 48.6% having 0, 30.2% having 1, 21.2% having 2 or more comorbidities. With a median follow‐up of 62.4 months among surviving participants, 2099 patients had an event and 1219 died. Continuous LCI similarly predicted both 1‐year mortality (c‐statistic = 0.654) and OS (c‐statistic = 0.655), while it showed a weaker but still statistically significant predictive ability for lymphoma‐specific (c‐statistics = 0.617) and event‐free (c‐statistic = 0.574) survival. Participants with 1 (HR = 1.21, 95% CI 1.05–1.39) and 2+ (HR = 1.80, 95% CI 1.56–2.08) comorbidities had inferior OS compared to those with no comorbidities after adjustment for age and sex (c‐statistic = 0.654), and performance strengthened after adjustment for the International Prognostic Index (c‐statistic = 0.672). LCI predicted OS most strongly in marginal zone (c‐statistics = 0.748) and weakest in T‐cell (c‐statistic = 0.579) lymphoma. The cumulative incidence of death due to lymphoma, lymphoma treatment, and other causes all increased with increasing comorbidities, with the greatest increase observed for death due to other causes. The LCI performs comparable to other published comorbidity indices, supporting its use in the LEO cohort to better model real‐world outcomes and more generally providing an approach to implementing comorbidity indices in cancer survivorship cohorts.